Patient Square Capital LP Invests $4.38 Million in uniQure N.V. $QURE

Patient Square Capital LP bought a new stake in shares of uniQure N.V. (NASDAQ:QURE) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 75,000 shares of the biotechnology company’s stock, valued at approximately $4,378,000. uniQure accounts for about 1.2% of Patient Square Capital LP’s portfolio, making the stock its 17th biggest holding.

A number of other institutional investors have also recently bought and sold shares of the stock. Jefferies Financial Group Inc. acquired a new stake in uniQure during the 2nd quarter worth about $29,217,000. JPMorgan Chase & Co. increased its position in shares of uniQure by 471.7% in the second quarter. JPMorgan Chase & Co. now owns 1,807,685 shares of the biotechnology company’s stock worth $25,199,000 after acquiring an additional 1,491,486 shares in the last quarter. Sofinnova Investments Inc. raised its holdings in shares of uniQure by 185.5% during the second quarter. Sofinnova Investments Inc. now owns 1,558,356 shares of the biotechnology company’s stock valued at $21,723,000 after acquiring an additional 1,012,585 shares during the period. Balyasny Asset Management L.P. lifted its position in shares of uniQure by 2,054.1% in the 2nd quarter. Balyasny Asset Management L.P. now owns 536,968 shares of the biotechnology company’s stock valued at $7,485,000 after acquiring an additional 512,040 shares in the last quarter. Finally, Ameriprise Financial Inc. boosted its stake in uniQure by 38.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 761,948 shares of the biotechnology company’s stock worth $10,622,000 after purchasing an additional 212,218 shares during the period. Hedge funds and other institutional investors own 78.83% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on QURE shares. Cantor Fitzgerald reissued an “overweight” rating on shares of uniQure in a research note on Wednesday, January 14th. Stifel Nicolaus lowered their price target on uniQure from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Thursday, December 11th. Wells Fargo & Company reduced their price objective on uniQure from $80.00 to $60.00 and set an “overweight” rating for the company in a research note on Wednesday, November 12th. Weiss Ratings restated a “sell (d-)” rating on shares of uniQure in a research report on Wednesday, January 21st. Finally, Benchmark reiterated a “buy” rating on shares of uniQure in a report on Tuesday, November 4th. Ten research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and a consensus price target of $58.33.

Insider Activity at uniQure

In other uniQure news, Director Jack Kaye sold 6,390 shares of uniQure stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the completion of the sale, the director directly owned 20,439 shares in the company, valued at $557,575.92. The trade was a 23.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $24.62, for a total transaction of $630,592.06. Following the completion of the sale, the director directly owned 32,342 shares of the company’s stock, valued at $796,260.04. This represents a 44.19% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 4.79% of the company’s stock.

Trending Headlines about uniQure

Here are the key news stories impacting uniQure this week:

• Positive Sentiment: Technical strength signal — coverage notes uniQure met an 80-plus relative strength benchmark, which can attract momentum investors and offset some selling pressure. Read More.
• Neutral Sentiment: Near-term catalyst — uniQure is scheduled to release earnings this week; results and guidance could swing sentiment and either aggravate or alleviate current selling related to the lawsuits. Read More.
• Negative Sentiment: Class-action filing by Kessler Topaz alleges securities fraud covering the Sept. 24–Oct. 31, 2025 period and sets an April 13, 2026 lead‑plaintiff deadline — this is a direct legal headline likely to weigh on the stock. Read More.
• Negative Sentiment: Multiple law firms (Schall, Faruqi & Faruqi, Pomerantz, Rosen, DJS, Bronstein Gewirtz & Grossman, Bernstein Liebhard, Portnoy, ClaimsFiler and others) have issued investor alerts and filings reminding shareholders of deadlines — the volume of notices magnifies perceived risk and creates sustained news flow and potential selling pressure. Read More.
• Negative Sentiment: Investor outreach emphasizes recoveries for specific loss thresholds and encourages lead‑plaintiff motions — if a strong lead plaintiff emerges, the case could proceed aggressively, increasing potential cost and uncertainty for the company. Read More.

uniQure Stock Performance

Shares of NASDAQ QURE opened at $23.43 on Monday. The company has a debt-to-equity ratio of 0.23, a current ratio of 7.12 and a quick ratio of 7.12. uniQure N.V. has a one year low of $7.76 and a one year high of $71.50. The business’s 50-day moving average price is $23.60 and its two-hundred day moving average price is $29.55. The company has a market capitalization of $1.46 billion, a P/E ratio of -5.34 and a beta of 0.66.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.